Personified prevention of diseases under the conditions of the Far North
S. Trofimova, A. Trofimov, A. Koryakin, A. Chubukin, V. Ternovoy · 2016 · Vrach. 2016;(6):64–66
Related evidence maps: Military & occupational ↗
Reported findings and study design
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
Dose, route and schedule
One capsule of the assigned preparation daily for 20 days. Products were selected by risk assessment; all six products were not given to every participant.
Protocol source ↗ · Original PDF p.65
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Sick-leave certificates | 18 → 10 | 2014 → 2015; whole program |
| Days unfit for work | 119 → 60 | 2014 → 2015; whole program |
| Seasonal morbidity | No statistically reliable improvement reported | |
| Narrative/table discrepancy | Narrative 43.4% decrease; Table 2 gives 119 → 60 days | Unresolved source discrepancy; not interchangeable figures |
Table 2 · Chronic-disease recurrence-related sick leave
| Measure | 2014 | 2015 |
|---|---|---|
| Sick-leave certificates | 18 | 10 |
| Days unfit for work | 119 | 60 |
Historical comparison for the shared 113-worker program. Not preparation-specific results.
One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.
Source for the extracted data ↗ · Checked 2026-11-01
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Original PDF, clinical table checked
Related-report group: gazprom-urengoy-2015-113. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original publisher PDF methods and clinical table checked; table visually verified.
Recorded source-check date: 2026-11-01. This date does not imply a completed systematic review.
Source type: Journal publication
Citation and original source
Original source: S. Trofimova, A. Trofimov, A. Koryakin, A. Chubukin, V. Ternovoy. Personified prevention of diseases under the conditions of the Far North Vrach. 2016;(6):64–66 2016.
Molekul research summary: https://molekul.io/research/gazprom-urengoy-2016. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Endoluten
Pineal-derived low-molecular-weight peptide mixture named in the original 113-worker Gazprom program. The paper reports program-level sick leave, without an Endoluten-specific effect.
Cerluten
Brain-associated tissue-peptide preparation named in risk-based assignments in the 113-worker Gazprom program and in institute reports. Shared program findings do not isolate Cerluten.
Vesugen
A peptide research entry in the Khavinson evidence map. Direct studies, related extract findings, institute reports and unresolved claims are distinguished below.
Crystagen
A product named in the originating-institute clinical-report collection. Experimental sequence, marketed formulation and clinical preparation must be checked separately.
Pinealon
A peptide research entry in the Khavinson evidence map. Direct studies, related extract findings, institute reports and unresolved claims are distinguished below.
Cartalax
Cartalax is an AED tripeptide studied in human dental surgery and a patent-reported knee-osteoarthritis comparison. The dental paper reports improved jaw-bone healing; the patent reports pain and mobility changes without substantial X-ray change. PCC is a separate cartilage-extract preparation.